Emily R. Winslow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emily R. Winslow has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Ryan K. Schmocker
Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
6 shared publications Linda M. Cherney Stafford
Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison
5 shared publicationsPejman Radkani
MedStar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, District of Columbia
5 shared publicationsAradhya Nigam
Department of Surgery, MedStar Georgetown University Hospital, Washington, DC, USA
4 shared publicationsGlen E. Leverson
4 shared publicationsThomas M. Fishbein
MedStar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, District of Columbia
4 shared publications
Latest Publications
- 7 March 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 307, 189-196
The Role of Markedly Elevated Cyst Carcinoembryonic Antigen in Risk-Stratifying Pancreatic Cysts
- 7 March 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 307, 189-196
The Role of Markedly Elevated Cyst Carcinoembryonic Antigen in Risk-Stratifying Pancreatic Cysts
- 14 November 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 240, 116088
Impact of prior cholecystectomy on diagnosis and outcomes of choledochal cyst resection in adults
- 14 November 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 240, 116088
Impact of prior cholecystectomy on diagnosis and outcomes of choledochal cyst resection in adults
- 18 May 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 237, 115765
Approach to postpancreatectomy care Impacts outcomes: Retrospective Validation of the PORSCH trial
- 18 May 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 237, 115765
Approach to postpancreatectomy care Impacts outcomes: Retrospective Validation of the PORSCH trial
- 20 January 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (1) , 77-87
Characteristics and malignancy rates of adult patients diagnosed with choledochal cyst in the West: a systematic review
- 20 January 2024
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 28 (1) , 77-87
Characteristics and malignancy rates of adult patients diagnosed with choledochal cyst in the West: a systematic review
- 1 January 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (1) , e230225
Invited Commentary: Symbiotic Relationship between the Pancreatic Surgeon and the Pancreatic Imager: Necessity of Reciprocal Communication
- 1 January 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (1) , e230225
Invited Commentary: Symbiotic Relationship between the Pancreatic Surgeon and the Pancreatic Imager: Necessity of Reciprocal Communication
- Open Access
- 10 December 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (3) , 1748-1753
Early Detection of Circulating Tumor DNA Postoperatively Enables Discovery of Resectable Metastatic Disease in a Patient with Colon Cancer
Currently, serum carcinoembryonic agent (CEA) along with contrast-enhanced imaging and colonoscopy are used for evaluation of recurrence of colorectal cancer. However, CEA is an unreliable and nonspecific biomarker that may fail to rise and signal relapse. Analysis of circulating tumor DNA (ctDNA) in patients offers a minimally invasive method to assess risk of relapse several months ahead of conventional clinical means. Here, we report the case of a colon adenocarcinoma with postoperative liver metastasis diagnosed early by ctDNA measurement, using a personalized NGS-mPCR assay. While ctDNA levels continued to rise, CEA levels tested negative. Metastatic relapse to the liver was promptly confirmed by PET/CT scan. The patient underwent a successful metastasectomy with curative intent. Following surgery, the patient exhibited no evidence of disease and ctDNA levels remained negative. Our case report suggests that the early detection of postoperative molecular residual disease by means of ctDNA measurement can accurately predict mCRC relapse in cases where CEA levels fail to increase. Close monitoring of ctDNA levels during the postoperative period can allow for earlier intervention and more favorable outcomes in relapsing mCRC patients.
- 10 December 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (3) , 1748-1753
Open AccessEarly Detection of Circulating Tumor DNA Postoperatively Enables Discovery of Resectable Metastatic Disease in a Patient with Colon Cancer
Currently, serum carcinoembryonic agent (CEA) along with contrast-enhanced imaging and colonoscopy are used for evaluation of recurrence of colorectal cancer. However, CEA is an unreliable and nonspecific biomarker that may fail to rise and signal relapse. Analysis of circulating tumor DNA (ctDNA) in patients offers a minimally invasive method to assess risk of relapse several months ahead of conventional clinical means. Here, we report the case of a colon adenocarcinoma with postoperative liver metastasis diagnosed early by ctDNA measurement, using a personalized NGS-mPCR assay. While ctDNA levels continued to rise, CEA levels tested negative. Metastatic relapse to the liver was promptly confirmed by PET/CT scan. The patient underwent a successful metastasectomy with curative intent. Following surgery, the patient exhibited no evidence of disease and ctDNA levels remained negative. Our case report suggests that the early detection of postoperative molecular residual disease by means of ctDNA measurement can accurately predict mCRC relapse in cases where CEA levels fail to increase. Close monitoring of ctDNA levels during the postoperative period can allow for earlier intervention and more favorable outcomes in relapsing mCRC patients.
- Open Access
- 23 April 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (10) , 3915-3923
Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group
Background Pancreatic neuroendocrine tumors (PNETs) are often indolent; however, identifying patients at risk for rapidly progressing variants is critical, particularly for those with small tumors who may be candidates for expectant management. Specific growth rate (SGR) has been predictive of survival in other malignancies but has not been examined in PNETs. Methods A retrospective cohort study of adult patients who underwent PNET resection from 2000 to 2016 was performed utilizing the multi-institutional United States Neuroendocrine Study Group database. Patients with ≥ 2 preoperative cross-sectional imaging studies at least 30 days apart were included in our analysis (N = 288). Patients were grouped as “high SGR” or “low SGR.” Demographic and clinical factors were compared between the groups. Kaplan–Meier and log-rank analysis were used for survival analysis. Cox proportional hazard analysis was used to assess the impact of various clinical factors on overall survival (OS). Results High SGR was associated with higher T stage at resection, shorter doubling time, and elevated HbA1c (all P ≤ 0.01). Patients with high SGR had significantly decreased 5-year OS (63 vs 80%, P = 0.01) and disease-specific survival (72 vs 91%, P = 0.03) compared to those with low SGR. In patients with small (≤ 2 cm) tumors (N = 106), high SGR predicted lower 5-year OS (79 vs 96%, P = 0.01). On multivariate analysis, high SGR was independently associated with worse OS (hazard ratio 2.67, 95% confidence interval 1.05–6.84, P = 0.04). Conclusion High SGR is associated with worse survival in PNET patients. Evaluating PNET SGR may enhance clinical decision-making, particularly when weighing expectant management versus surgery in patients with small tumors.
- 23 April 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (10) , 3915-3923
Open AccessSpecific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group
Background Pancreatic neuroendocrine tumors (PNETs) are often indolent; however, identifying patients at risk for rapidly progressing variants is critical, particularly for those with small tumors who may be candidates for expectant management. Specific growth rate (SGR) has been predictive of survival in other malignancies but has not been examined in PNETs. Methods A retrospective cohort study of adult patients who underwent PNET resection from 2000 to 2016 was performed utilizing the multi-institutional United States Neuroendocrine Study Group database. Patients with ≥ 2 preoperative cross-sectional imaging studies at least 30 days apart were included in our analysis (N = 288). Patients were grouped as “high SGR” or “low SGR.” Demographic and clinical factors were compared between the groups. Kaplan–Meier and log-rank analysis were used for survival analysis. Cox proportional hazard analysis was used to assess the impact of various clinical factors on overall survival (OS). Results High SGR was associated with higher T stage at resection, shorter doubling time, and elevated HbA1c (all P ≤ 0.01). Patients with high SGR had significantly decreased 5-year OS (63 vs 80%, P = 0.01) and disease-specific survival (72 vs 91%, P = 0.03) compared to those with low SGR. In patients with small (≤ 2 cm) tumors (N = 106), high SGR predicted lower 5-year OS (79 vs 96%, P = 0.01). On multivariate analysis, high SGR was independently associated with worse OS (hazard ratio 2.67, 95% confidence interval 1.05–6.84, P = 0.04). Conclusion High SGR is associated with worse survival in PNET patients. Evaluating PNET SGR may enhance clinical decision-making, particularly when weighing expectant management versus surgery in patients with small tumors.